FDA approval for Eli Lilly and Co.'s migraine prevention therapy, Emgality (galcanezumab-gnlm), completes a trio of anticipated 2018 calcitonin gene-related peptide (CGRP) entries into a fiercely competitive field where months of free drug is par for the course. The green light follows an earlier September approval for Teva Pharmaceutical Industries Ltd.'s Ajovy (fremanezumab-vfrm) and, in May, for Amgen Inc.'s Aimovig (erenumab-aooe).